Q2 10-Q for period ended June 30, 2026. Confirms March 30, 2026 Business Combination Agreement with Carvix remains in place; no S-4, proxy, vote, or close update in this filing. Trust Account $176,476,946 as of June 30, 2026, including dividends earned since IPO. Rights still entitle holder to one-fifth (0.20) of one Class A ordinary share on business combination consummation. Close-path (Pulse) unchanged post-DA; cash (V) continues to accrete in trust.

Conversion 1/5